Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)

CAPS Rating: 3 out of 5

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.

Recs

2
Player Avatar cashsage (29.83) Submitted: 4/22/2009 12:33:59 PM : Underperform Start Price: $2.55 PLX Score: -72.50

PLX has a too high valuation compared to its sales potential. Its current sales are nil, and so is one of the most loss making companies.

Featured Broker Partners


Advertisement